Adverum_Primary_Medium.png
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) --  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
November 04, 2022 12:08 ET | Adverum Biotechnologies, Inc.
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
October 27, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
September 30, 2022 16:45 ET | Adverum Biotechnologies, Inc.
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
September 23, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
September 23, 2022 08:00 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
LUNA Phase 2 Study in Wet AMD - Study Design
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
September 14, 2022 08:00 ET | Adverum Biotechnologies, Inc.
- LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
August 26, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...